KR870005648A - 슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체 - Google Patents

슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체 Download PDF

Info

Publication number
KR870005648A
KR870005648A KR860010569A KR860010569A KR870005648A KR 870005648 A KR870005648 A KR 870005648A KR 860010569 A KR860010569 A KR 860010569A KR 860010569 A KR860010569 A KR 860010569A KR 870005648 A KR870005648 A KR 870005648A
Authority
KR
South Korea
Prior art keywords
pseudomonas
composition
antibody
iats
human
Prior art date
Application number
KR860010569A
Other languages
English (en)
Other versions
KR910008361B1 (ko
Inventor
더블유. 시아닥 안토니
제이. 로석 매
Original Assignee
원본미기재
제네틱 시스팀스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 제네틱 시스팀스 코포레이션 filed Critical 원본미기재
Publication of KR870005648A publication Critical patent/KR870005648A/ko
Application granted granted Critical
Publication of KR910008361B1 publication Critical patent/KR910008361B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 슈도모나스 이루지노사의 다수(전체는 아님)의 IATS항원형과 특별히 결합할 수 잇는 인체 단일분지계 항체 또는 그 결합단편으로 구성되는 조성물.
  2. 제1항에 있어서, 상기 항체가 최소한 2 이상의 IATS항원형에 대한 생체내에서의 보호작용을 갖는이 특징인 조성물.
  3. 제1항에 있어서, 상기 항체가 슈도모나스 이루지노사중의 어는 피셔 면역형과 비반응성인 것이 특징인 조성물.
  4. 제1항에 있어서, 상기 항체가 슈도모나스 이루지노사중의 1피셔 면역형과 비반응성인 것이 특징인 조성물.
  5. 제1항에 있어서, 상기 항체가 슈도모나스 이루지노사중의 2 또는 그 이상의 피셔 면역형과 반응할수 있는 것이 특징인 조성물.
  6. 제1항 내지 제5항중의 어느 한항에 따른 조성물과 생물학적으로 허용되는 담체로 구성되는 것이 특징인 조성물.
  7. 제1항 내지 제5항중에 따른 조성물의 치료학상 또는 예방학상 유효량을 숙주에 투여함을 특징으로 하는 슈도모나스 이루지노상로 인하여 균혈중에 걸리기 쉬운 환자 또는 기타 질병에 걸린 환자를 치료하는 방법.
  8. 슈도모나스 이루지노사의 전체보다 적은, 그러나 최소한 2 이상의 IATS 항원형과 특별히 반응하는 인체 단일분지계 항체를 분비하는 불멸의 변형세포계열.
  9. 제8항에 있어서, ATCC 제 CRL 8941호, 9171호 또는 9258호로 지정된 세포계열.
  10. 제8항에 따른 세포계열에 의해서 제조된 단일분지계 항체와 반응하는 에피토프와 반응할 수 있는 인체의 단일분지계 항체.
  11. 슈도모나스 이루지노사의 전체보다 적고, 그러나 최소한 2 이상인 IATS항원형과 반응하는 최소한 1 이상의 인체 단일분지계 항체를 함유하는 단일분지계 항체 조성물과 상기 항체들과 공유결합된 검파할 수 있는 암호를 구비한 라벨로 구성됨을 특징으로 하는 슈도모나스 이루지노사의 존재를 검색하는데 사용되는 도구.
  12. 슈도모나스 이루지노사의 최소한 2 이상의 IATS항원형에 대하여 보호하는 인체의 단일분지계 항체와 인체 혈장 면역글로불린으로 부터 얻은 감마 글로블린 유분과(또는)생물학적으로 허용되는 담체를 혼합하여 된 슈도모나스 이루지노사의 감염을 치료 또는 예방하는데 사용되는 제약조성물.
  13. 슈도모나스 이루지노사의 최소한 2 이상의 IATS항원형과 반응하는 단일분지계 항체와 시료를 혼합하고 복합체 형서물을 검출하는 것을 특징으로 하는 시료중에 슈도모나스 이루지노사의 존재를 측정하는 방법.
  14. 최소한 2가지 이상의 인체 단일분지계 항체(이 항체중의 최소한 1가지 이상의 슈도모나스 이루지노사의 최소한 2 이상의 IATS항원형에 대하여 보호작용을 가짐)와 항균제, 인체 혈장으로 부터 얻은 감마 글로불린 유분과 (또는) 생물학적으로 허용되는 담체를 혼합시킴을 특징으로 하는 슈도모나스 이루지노사 감염을 치료 또는 예방하는데 사용하는 제약조성물을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860010569A 1985-12-10 1986-12-10 슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체 KR910008361B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80739485A 1985-12-10 1985-12-10
US807,394 1985-12-10
US93117986A 1986-11-24 1986-11-24
US931179 1986-11-24
US931,179 1986-11-24
US807394 1986-11-24

Publications (2)

Publication Number Publication Date
KR870005648A true KR870005648A (ko) 1987-07-06
KR910008361B1 KR910008361B1 (ko) 1991-10-12

Family

ID=27123006

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860010569A KR910008361B1 (ko) 1985-12-10 1986-12-10 슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체

Country Status (21)

Country Link
US (4) US5378812A (ko)
JP (1) JPH07116237B2 (ko)
KR (1) KR910008361B1 (ko)
CN (1) CN86108380A (ko)
AT (1) AT400441B (ko)
BE (1) BE905890A (ko)
CH (1) CH677362A5 (ko)
DE (1) DE3642095C2 (ko)
DK (1) DK594586A (ko)
FI (1) FI86377C (ko)
FR (1) FR2593826B1 (ko)
GB (1) GB2185266B (ko)
HU (1) HUT41836A (ko)
IE (1) IE59741B1 (ko)
IT (1) IT1199735B (ko)
LU (1) LU86711A1 (ko)
NL (1) NL8603132A (ko)
NO (1) NO178718C (ko)
NZ (1) NZ218499A (ko)
PT (1) PT83894B (ko)
SE (1) SE468831B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
DK172840B1 (da) * 1986-07-03 1999-08-09 Genetic Systems Corp Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
AU591017B2 (en) * 1986-12-15 1989-11-23 Mitsui Toatsu Chemicals Inc. Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
US5521085A (en) * 1986-12-15 1996-05-28 Mitsui Toatsu Chemicals, Inc. Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes
JPH01197500A (ja) * 1988-01-29 1989-08-09 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
EP0382031A3 (en) * 1989-02-10 1991-06-26 Miles Inc. Monoclonal antibodies in immune serum globulin
US4994269A (en) * 1989-03-17 1991-02-19 Miles Inc. Topical use of antibodies for prevention or treatment of pseudomonas infections
CA2028815A1 (en) * 1989-03-20 1990-09-21 Yuko Mizuno Human monoclonal antibodies having reactivity with pseudomonas aeruginosa, cells capable of producing the same, methods for production thereof and pharmaceutical preparations thereof
JPH02283294A (ja) * 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
US5858728A (en) * 1991-03-13 1999-01-12 Common Services Agency Monoclonal antibody against LPS core
US20030096315A1 (en) 2000-05-03 2003-05-22 Sanders Mitchell C. Device for detecting bacterial contamination and method of use
CA2474458A1 (en) * 2002-01-31 2003-08-07 Mitchell C. Sanders Method for detecting microorganisms
US20060292562A1 (en) * 2002-05-29 2006-12-28 Pollard Harvey B Methods of identifying genomic and proteomic biomarkers for cystic fibrosis, arrays comprising the biomarkers and methods of using the arrays
ATE544354T1 (de) * 2002-11-26 2012-02-15 Univ Chicago Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
WO2004087942A2 (en) * 2003-01-31 2004-10-14 Ethicon, Inc. Method for detecting escherichia coli
DE602004011105T2 (de) 2003-11-03 2008-12-18 Ethicon, Inc. Verfahren, peptide und biosensoren mit eignung zum nachweis eines breiten spektrums von bakterien
EP1690875A1 (en) * 2005-02-14 2006-08-16 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
US8788049B2 (en) * 2006-05-01 2014-07-22 Bioness Neuromodulation Ltd. Functional electrical stimulation systems
US20100272736A1 (en) * 2009-02-04 2010-10-28 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2011102551A1 (en) * 2010-02-18 2011-08-25 Meiji Seika Kaisha, Ltd. Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
JPS59137497A (ja) * 1983-01-20 1984-08-07 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
JPS58216125A (ja) * 1982-06-09 1983-12-15 Asahi Chem Ind Co Ltd ヒト抗体の産生方法
JPS5929622A (ja) * 1982-08-10 1984-02-16 Meiji Seika Kaisha Ltd モノクロ−ナル抗体、その製造法およびその用途
EP0286099A3 (en) * 1983-05-06 1988-12-21 Velos Group Monoclonal antibodies reactive with endotoxin core
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
EP0168422A1 (en) * 1983-12-12 1986-01-22 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
US4683196A (en) * 1983-12-12 1987-07-28 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
JPS60248625A (ja) * 1984-05-25 1985-12-09 Mitsui Toatsu Chem Inc 抗緑膿菌モノクロ−ナル抗体、その製法ならびに用途
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
EP0233289B1 (en) * 1984-12-26 1993-03-10 Teijin Limited Hybridomas producing anti-pseudomonas aeruginosa human monoclonal antibody
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
JPS6229175A (ja) * 1985-07-29 1987-02-07 Nippon Telegr & Teleph Corp <Ntt> 電界効果型トランジスタの製造方法
EP0211352B1 (en) * 1985-08-01 1994-03-16 Miles Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
DK172840B1 (da) * 1986-07-03 1999-08-09 Genetic Systems Corp Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies

Also Published As

Publication number Publication date
DK594586D0 (da) 1986-12-10
BE905890A (fr) 1987-06-10
LU86711A1 (fr) 1988-07-14
GB8629540D0 (en) 1987-01-21
NO864971L (no) 1987-06-11
SE468831B (sv) 1993-03-29
US5627067A (en) 1997-05-06
HUT41836A (en) 1987-05-28
GB2185266A (en) 1987-07-15
FR2593826A1 (fr) 1987-08-07
DK594586A (da) 1987-06-11
CN86108380A (zh) 1987-10-28
FI86377C (fi) 1992-08-25
NO864971D0 (no) 1986-12-10
PT83894A (en) 1987-01-01
FI86377B (fi) 1992-05-15
DE3642095A1 (de) 1987-07-02
KR910008361B1 (ko) 1991-10-12
IT8622630A0 (it) 1986-12-10
GB2185266B (en) 1990-09-05
FI865027A0 (fi) 1986-12-10
IE59741B1 (en) 1994-03-23
PT83894B (pt) 1989-07-31
NO178718C (no) 1996-05-22
NZ218499A (en) 1990-04-26
JPS62187417A (ja) 1987-08-15
ATA328286A (de) 1995-05-15
SE8605295L (sv) 1987-06-11
US5628996A (en) 1997-05-13
JPH07116237B2 (ja) 1995-12-13
US5662905A (en) 1997-09-02
CH677362A5 (ko) 1991-05-15
IT1199735B (it) 1988-12-30
FR2593826B1 (fr) 1990-11-16
NO178718B (no) 1996-02-12
US5378812A (en) 1995-01-03
NL8603132A (nl) 1987-07-01
DE3642095C2 (de) 1998-10-01
AT400441B (de) 1995-12-27
FI865027A (fi) 1987-06-11
SE8605295D0 (sv) 1986-12-10
IE863230L (en) 1987-06-10

Similar Documents

Publication Publication Date Title
KR870005648A (ko) 슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체
Pfaffenbach et al. Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes.
Fu et al. Similar idiotypic specificity for the membrane IgD and IgM of human B lymphocytes
Podack et al. Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation.
Fearon et al. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins
Mollnes et al. Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma
Cooper Formation and function of a complex of the C3 proactivator with a protein from cobra venom
DE68924850D1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
Tedesco et al. Two types of dysfunctional eighth component of complement (C8) molecules in C8 deficiency in man. Reconstitution of normal C8 from the mixture of two abnormal C8 molecules.
Schmidt et al. A secreted receptor related to M1 protein of Streptococcus pyogenes binds to fibrinogen, IgG, and albumin
Grov Human IgM interacting with staphylococcal protein A
AU1648588A (en) A one-step immunoassay for the determination of antigen-specific antibodies of one of the immunoglobulin classes a,m,d or e, and an agent suitable for this purpose
Brandtzaeg Blocking effect of J chain and J‐chain antibody on the binding of secretory component to human IgA and IgM
Eggertsen et al. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
Martonosi et al. The effect of anti-ATPase antibodies upon the Ca++ transport of sarcoplasmic reticulum
Brandtzaeg Human secretory component—IV. Aggregation and fragmentation of of free secretory component
Rubinstein et al. QUANTITATIVE STUDIES ON TUMOR ENHANCEMENT IN MICE: I. ENHANCEMENT OF SARCOMA I INDUCED BY IgM, IgG1, AND IgG2
KR880001815A (ko) 슈도모나스 에루기노사 편모에 대한 단일클론항체
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
Lefvert et al. Immunoglobulins in myasthenia gravis: effect of human lymph IgG 3 and F (ab ‘) 2 fragments on a cholinergic receptor preparation from Torpedo marmorata
Kakimoto et al. Characterization of the Fv fragment isolated from a human immunoglobulin M
Wilson Studies on the products of peptic digestion of IgA
Sesardic et al. The First International Standard for Antitetanus Immunoglobulin, Human; pharmaceutical evaluation and international collaborative study
Erntell et al. Non‐Immune IgG F (ab′) 2 Binding to Group C and G Streptococci Is Mediated by Structures on γ Chains
Franěk et al. Different types of precipitating antibodies in early and late porcine anti-dinitrophenyl sera

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee